Back to Authors

Eden, Edward

https://orcid.org/0000-0002-1048-1990

A5010955414 | I98704320

Mayo Clinic

Icahn School of Medicine at Mount Sinai

Citations 7

Comparing Clinical Characteristics and Outcomes in Patients with Non-Cystic Fibrosis Bronchiectasis with Non-Tuberculous Mycobacteria and/or Pseudomonas Aeruginosa Within the US Bronchiectasis and NTM Research Registry

D104. PHENOTYPES, PROGNOSTIC TOOLS, AND ADJUNCT THERAPIES IN COUGH, CF AND NON-CF BRONCHIECTASIS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A7764-A7764

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a7764

The Association of Chronic Macrolide Treatment and Incident Isolation of Non-Tuberculous Mycobacteria in Patients with Bronchiectasis

D12. EPIDEMIOLOGY AND THERAPY IN CF AND NON-CF BRONCHIECTASIS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6200-A6200

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6200

Pulmonary Nontuberculous Mycobacterial Infection in Patients in the U.S. Bronchiectasis Research Registry: Use of Antibiotic Therapy and Adverse Events

B106. BREAKTHROUGHS IN NTM DIAGNOSIS AND TREATMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A4358-A4358

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4358

Pseudomonas Aeruginosa Associated with Severity of Non-Cystic Fibrosis Bronchiectasis Measured by the Modified Bronchiectasis Severity Score (BSI) and the FACED: The US Bronchiectasis and NTM Research Registry (BRR) Study

C105. BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5716-A5716

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5716

Airway Clearance in Non-Cystic Fibrosis Bronchiectasis: Analysis from the United States Bronchiectasis Research Registry

C105. BRONCHIECTASIS: FROM CLINICAL PHENOTYPES TO TREATMENT | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5700-A5700

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5700

The Prevalence and Significance of Staphylococcus aureus in Patients with Non–Cystic Fibrosis Bronchiectasis

Annals of the American Thoracic Society | January 18, 2018 | Volume: 15 | Issue: 3 | Pages: 365-370

10.1513/annalsats.201706-426oc | PMID 29345970

Abstract Rationale Staphylococcus aureus is commonly cultured from the sputum of patients with bronchiectasis; however, little is known about the prevalence of the organism in these patients, the characteristics of patients who have grown the organism, or its implications. Objectives Determine the relationship between S. aureus and pulmonary function, frequency of exacerbations, and frequency of hospitalization in patients with bronchiectasis Methods The Bronchiectasis Research Registry is a database of adults with non–cystic fibrosis bronchiectasis identified from 13 sites within the United States. Baseline and follow-up demographic, spirometric, microbiologic, and therapeutic data were entered into a central web-based database. Patients were grouped into three cohorts based on their previous respiratory cultures at the time of entry into the Registry: 1) no prior S. aureus or glucose-nonfermenting gram-negative bacilli (NF-GNB) (Pseudomonas, Stenotrophomonas, or Burkholderia spp.); 2) prior S. aureus at least once; or 3) no prior S. aureus but prior NF-GNB at least once. The association between S. aureus isolation and pulmonary function and frequency of exacerbations and hospital admissions was assessed, both at baseline and after 1 year of follow-up. Results S. aureus was cultured from 94 of 830 patients (11.3%) included in the analysis. Patients who had grown S. aureus before entry into the Registry had a frequency of prior exacerbations and baseline pulmonary function that was between that of patients who had grown NF-GNB and those who had grown neither NF-GNB or S. aureus. Similarly, at the first follow-up visit after study entry, patients who had grown S. aureus had a frequency of exacerbations and hospitalizations that was between those of patients who had grown NF-GNB and those who had grown neither NF-GNB nor S. aureus. However, in multivariate analysis, S. aureus was not associated with pulmonary function, frequency of exacerbation, or hospital admissions. There were no significant differences in patient characteristics or outcomes between patients who had methicillin-sensitive and methicillin-resistant S. aureus. Conclusions Staphylococcus aureus does not appear to be an independent risk factor for severe disease in patients with bronchiectasis enrolled in the Bronchiectasis Research Registry.
The Prevalence of Alpha-1 Antitrypsin Deficiency Among Patients Found to Have Airflow Obstruction

COPD: Journal of Chronic Obstructive Pulmonary Disease | April 16, 2012 | Volume: 9 | Issue: 4 | Pages: 352-358

10.3109/15412555.2012.669433 | PMID 22506682